Rapport Therapeutics IncRAPP
Price$32.83

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $20MTTM through 30 Jun 2026
Net Income -$111.5MTTM through 30 Jun 2026
Free Cash Flow -$97.1MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%
EBITDA Margin-620.4%
Operating Margin-625.5%
Net Margin-557.4%

Returns

-26.4%ROE
-24.3%ROA

Balance Sheet Health

Debt / Equity0.03x
Current Ratio15.72x
Net Debt-$479.1Mnet cash position
Cash & Equivalents$63.6M

Quality Metrics

Altman Z-Score32.40
Piotroski F-Score1 / 9
FCF Margin-485.7%
Rule of 40-485.7
Earnings-Beat Rate75.0%

Multi-Year Trend

Diluted EPS-$3.03TTM
'23'24'25
FY2025: $-2.86

Dividend

No dividend

Capital Allocation

R&D Spend$136.7M
Capex Intensity2.3%

Segment Performance

No segment data available.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.